Search results for "Convulsants"

showing 10 items of 125 documents

Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients…

2017

Introduction: Stimulation-evoked focal to bilateral tonic-clonic seizure (FBTCS) can be a stressful and possibly harmful adverse event for patients during cortical stimulation (CS). We evaluated if drug load reduction of anti epileptic drugs (AEDs) during CS increases the risk of stimulation-evoked FBTCS. Material and methods: In this retrospective cohort study, we searched our local database for patients with drug resistant epilepsy who underwent invasive video-EEG monitoring and CS in the University Hospital la Fe Valencia from January 2006 to November 2016. The AED drug load was calculated with the defined daily dose. We applied a uni- and multivariate logistic regression model to estima…

0301 basic medicineAdultMalemedicine.medical_specialtyDrug Resistant EpilepsyNeurologyAdolescentDrug-Related Side Effects and Adverse ReactionsStimulation03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineEpilepsy surgerySeizuresmedicineOdds RatioHumansEpilepsy surgeryAdverse effectRetrospective Studiesbusiness.industryRetrospective cohort studyElectroencephalographyOdds ratioMiddle Agedmedicine.diseaseElectric Stimulation030104 developmental biologyDefined daily doseLogistic ModelsTreatment OutcomeNeurologyElectrical stimulationWithdrawalAnesthesiaDefined daily doseAnticonvulsantsEpilepsy GeneralizedFemaleNeurology (clinical)Epilepsies PartialEpilepsy Tonic-ClonicSafetybusinessGeneralized tonic-clonic seizure030217 neurology & neurosurgeryEpilepsybehavior : EB
researchProduct

Lacosamide in patients with temporal lobe epilepsy: An observational multicentric open-label study.

2016

Abstract Purpose The aim of this study was to evaluate the efficacy and tolerability of lacosamide (LCM) both as add-on therapy and monotherapy in patients with temporal lobe epilepsy (TLE) based on an observational, prospective, multicenter study. Methods We enrolled 100 patients (mean age: 43.4 ± 12.53 years, 57 females) with nonlesional TLE and TLE with hippocampal sclerosis (HS) that did not respond to the first drug and who were referred to epilepsy centers of the University of Catanzaro, University of Palermo, IRCSS Neuromed of Pozzilli, and Otto-von-Guericke University of Magdeburg. In this open-label, multicenter trial, patients were initiated on oral LCM as add-on therapy to first …

0301 basic medicineAdultMalemedicine.medical_specialtyLacosamideCohort Studies03 medical and health sciencesBehavioral NeuroscienceEpilepsyYoung Adult0302 clinical medicineLacosamideMulticenter trialInternal medicineAcetamidesMedicineHumansProspective StudiesAdverse effectProspective cohort studyHippocampal sclerosisbusiness.industryMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyNeurologyTolerabilityEpilepsy Temporal LobeAnesthesiaConcomitantAnticonvulsantsDrug Therapy CombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesEpilepsybehavior : EB
researchProduct

Apnea events in neonatal age: A case report and literature review.

2019

Abstract Background Among the most common autonomic signs visible in preterm neonates, apnea can represent the first sign of several neurologic and non-neurologic disorders, and seizure is a relatively infrequent cause. Herein authors present a case of neonatal autonomic apnea, discussing the polygraphic video-EEG features of this pathological entity and the differential diagnosis with central apnea and autonomic apnea. Case report A female preterm Caucasian infant (29 + 4 weeks' gestational age (GA)), first twin of a twin pregnancy, at birth was intubated and surfactant administration was performed. She was ventilated via invasive ventilation for three days, with subsequent weaning with no…

0301 basic medicineLevetiracetamCentral apneaVideo RecordingDiseasesInfant Premature Diseases0302 clinical medicinenewbornDiagnosisHypoxiaApneaSleep apneaGestational ageElectroencephalographyGeneral MedicineSleep Apnea CentralAnesthesiaNervous System Diseases; Bradycardia; Cyanosis; Diagnosis Differential; Humans; Hypoxia; Infant Newborn; Infant Premature; Infant Premature Diseases; ; Sleep ApneaBreathingAnticonvulsantsFemalemedicine.symptomInfant PrematureBradycardiaSleep ApneaContext (language use)Gestational AgeNODiagnosis Differential03 medical and health sciencesSeizuresHeart ratemedicineBradycardiaDiseases in TwinsHumansPrematureCyanosisbusiness.industryInfant NewbornInfantapneamedicine.disease030104 developmental biologyAutonomic Nervous System DiseasesDifferentialNervous System Diseasesbusinesspreterm030217 neurology & neurosurgeryneurologic disorders
researchProduct

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma

2021

A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of androgen receptor pathway. Therefore, effective drugs against both CRPC and NEPC are needed. We have previously described a dual role of mast cells (MCs) in prostate cancer, being capable to promote adenocarcinoma but also to restrain NEPC. This finding suggests that a molecule targeting both MCs and NEPC cells could be effective against prostate cancer. Using an in silico drug repurposing approach, here we identify the antiepileptic drug levetiracetam as a potential candidate for this purpose. We found that the protein…

0301 basic medicineMaleLevetiracetammast cellsneuroendocrine differentiationNeuroendocrine differentiationCell DegranulationAndrogen deprivation therapyProstate cancer0302 clinical medicineTumor Cells CulturedImmunology and AllergySV2AOriginal ResearchMembrane Glycoproteinsdrug repurposingCell Differentiationprostate cancerGene Expression Regulation NeoplasticMatrix Metalloproteinase 9030220 oncology & carcinogenesisAdenocarcinomaAnticonvulsantsLevetiracetammedicine.druglcsh:Immunologic diseases. AllergyImmunologyAntineoplastic AgentsMice TransgenicNerve Tissue Proteins03 medical and health sciencesmedicineAnimalsHumanstumor microenvironmentmouse modelsHigh-grade prostatic intraepithelial neoplasiadrug repurposing; mast cells; mouse models; neuroendocrine differentiation; prostate cancer; tumor microenvironmentCell Proliferationbusiness.industryDrug RepositioningProstatic NeoplasmsNeoplasms Experimentalmedicine.diseaseCarcinoma Neuroendocrinedrug repurposing mast cells mouse models neuroendocrine differentiation prostate cancer tumor microenvironmentAndrogen receptorMice Inbred C57BL030104 developmental biologyCancer researchlcsh:RC581-607business
researchProduct

Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes

2017

Targeted resequencing gene panels are used in the diagnostic setting to identify gene defects in epilepsy. We performed targeted resequencing using a 30-genes panel and a 95-genes panel in 349 patients with drug-resistant epilepsies beginning in the first years of life. We identified 71 pathogenic variants, 42 of which novel, in 30 genes, corresponding to 20.3% of the probands. In 66% of mutation positive patients seizures onset occurred before age 6 months. The 95-genes panel allowed a genetic diagnosis in 22 (6.3%) patients that would have otherwise been missed using the 30-gene panel. About 50% of mutations were identified in genes coding for sodium and potassium channel components. SCN2…

0301 basic medicineProbandMaleCDKL5Drug Resistancemedicine.disease_causeBioinformaticsEpilepsyAnticonvulsantSTXBP1Age of OnsetChildGenetics (clinical)AlleleMutationepilepsy; next-generation sequencing; gene panel; mutationPhenotypeMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria Infantile3. Good healthPhenotypeChild PreschoolAnticonvulsantsFemaleSequence AnalysisHumanAdolescentGenotypeGenetic Association StudieBiologyMECP203 medical and health sciencesGeneticgene panelGeneticsmedicineHumansGenetic Predisposition to DiseasePreschoolGeneAllelesGenetic Association StudiesGene Expression ProfilingInfant NewbornComputational BiologyInfantMolecular Sequence AnnotationDNASequence Analysis DNANewbornmedicine.disease030104 developmental biologyepilepsynext-generation sequencingmutation
researchProduct

Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased suscepti…

2021

There is a growing body of evidence demonstrating the significant involvement of the sigma-1 chaperone protein in the modulation of seizures. Several sigma-1 receptor (Sig1R) ligands have been demonstrated to regulate the seizure threshold in acute and chronic seizure models. However, the mechanism by which Sig1R modulates the excitatory and inhibitory pathways in the brain has not been elucidated. The aim of this study was to compare the susceptibility to seizures of wild type (WT) and Sig1R knockout (Sig1R−/−) mice in intravenous pentylenetetrazol (PTZ) and (+)-bicuculline (BIC) infusion-induced acute seizure and Sig1R antagonist NE-100-induced seizure models. To determine pos…

0301 basic medicinemedicine.medical_specialtyKnockoutGene ExpressionNitric Oxide Synthase Type IISigma-1 receptorConvulsantsAnisolesSigma-1 receptor Knockout GABA-B receptor Seizures Medial habenula NE-100BicucullineHippocampuslcsh:RC321-571Mice03 medical and health sciences0302 clinical medicineDownregulation and upregulationSeizuresInternal medicineGene expressionmedicineAnimalsReceptors sigmaGABA-B receptorGenetic Predisposition to DiseasePentylenetetrazolReceptorlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMice KnockoutHabenulaSigma-1 receptorPropylaminesSeizure thresholdChemistryMedial habenulaWild typeAntagonistReceptors GABA-A030104 developmental biologyEndocrinologyReceptors GABA-BNeurologyNE-100Pentylenetetrazole030217 neurology & neurosurgerymedicine.drugNeurobiology of Disease
researchProduct

Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies

2016

Objective: To test previous signals of a risk of orofacial cleft (OC) and clubfoot with exposure to the antiepileptic lamotrigine, and to investigate risk of other congenital anomalies (CA).Methods: This was a population-based case–malformed control study based on 21 EUROCAT CA registries covering 10.1 million births (1995–2011), including births to 2005 in which the clubfoot signal was generated and a subsequent independent study population of 6.3 million births. A total of 226,806 babies with CA included livebirths, stillbirths, and terminations of pregnancy following prenatal diagnosis. First-trimester lamotrigine monotherapy exposure in OC cases and clubfoot cases was compared to other …

115congenital anomalies ; orofacial clefts ; lamotrigine ; pregnancy0302 clinical medicinePregnancyOdds RatioRegistries030212 general & internal medicineEPILEPSYeducation.field_of_studyTriazinesObstetricsAbsolute risk reductionANTIEPILEPTIC DRUGSAbnormalities Drug-InducedCleft PalateEuropeAnesthesiaINCREASED FREQUENCYAnticonvulsantsFemalemedicine.drugAdultRisk61medicine.medical_specialtyCleft LipPopulationPrenatal diagnosisLamotrigineLamotrigineSensitivity and SpecificityArticle03 medical and health sciencesJournal ArticlemedicineHumansAbnormalities Drug-Induced/epidemiology; Adult; Anticonvulsants/adverse effects; Anticonvulsants/therapeutic use; Case-Control Studies; Cleft Lip/chemically induced; Cleft Lip/epidemiology; Cleft Palate/chemically induced; Cleft Palate/epidemiology; Epilepsy/drug therapy; Epilepsy/epidemiology; Europe/epidemiology; Female; Humans; Odds Ratio; Pregnancy; Pregnancy Complications/drug therapy; Pregnancy Complications/epidemiology; Pregnancy Trimester First; Registries; Risk; Sensitivity and Specificity; Triazines/adverse effects; Triazines/therapeutic useMALFORMATIONSeducationPregnancy53business.industryCLUBFOOTCase-control studyOdds ratio228medicine.diseaseConfidence intervalPregnancy ComplicationsPregnancy Trimester FirstPALATECase-Control StudiesREGISTRYNeurology (clinical)business030217 neurology & neurosurgeryNeurology
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures

2022

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32-56) years were included. During the 1-year study period, sustained se…

AdultFreedomfocal seizuresEpilepsiesSettore MED/26Double-Blind MethodDrug Therapyantiseizure medication; brivaracetam; focal seizures; seizure freedom; sodium channel blockers; Adult; Double-Blind Method; Drug Therapy Combination; Freedom; Humans; Middle Aged; Pyrrolidinones; Seizures; Treatment Outcome; Anticonvulsants; Epilepsies PartialSeizuresseizure freedomHumansanti-seizure medication; focal seizures; epilepsyantiseizure medicationbrivaracetamanti-seizure medicationMiddle AgedPyrrolidinonesTreatment OutcomeNeurologysodium channel blockersCombinationepilepsyDrug Therapy CombinationAnticonvulsantsNeurology (clinical)Epilepsies PartialPartial
researchProduct

Cortisol levels and seizures in adults with epilepsy: A systematic review

2018

Stress has been suggested as a trigger factor for seizures in epilepsy patients, but little is known about cortisol levels, as indicators of stress, in adults with epilepsy. This systematic review summarizes the evidence on this topic. Following PRISMA guidelines, 38 articles were selected: 14 analyzing basal cortisol levels, eight examining antiepileptic drugs (AEDs) effects, 13 focused on seizure effects, and three examining stress. Higher basal cortisol levels were found in patients than in healthy people in studies with the most homogeneous samples (45% of 38 total studies). Despite heterogeneous results associated with AEDs, seizures were related to increases in cortisol levels in 77% …

AdultHypothalamo-Hypophyseal SystemEpilepsyHydrocortisonebusiness.industryCognitive NeurosciencePhysiologymedicine.diseaseBehavioral NeuroscienceEpilepsyFunctional brainBasal (phylogenetics)Neuropsychology and Physiological Psychologymedicine.anatomical_structureSeizuresHomogeneousmedicineHumansAnticonvulsantsChronic stressAcute stressbusinessCortisol levelStress PsychologicalHypothalamic–pituitary–adrenal axisNeuroscience & Biobehavioral Reviews
researchProduct